Clinical Trials Logo

SARS-CoV-2 clinical trials

View clinical trials related to SARS-CoV-2.

Filter by:

NCT ID: NCT05903118 Completed - SARS-CoV-2 Clinical Trials

A Phase I/II Study to Evaluate a SARS-CoV-2 mRNA Vaccine in Healthy Adults

Start date: January 8, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The phase I/II study is to evaluate the safety and immunogenicity of SARS-COV-2 mRNA Vaccine (RBMRNA-176) at different doses in healthy subjects aged 18 years and older.

NCT ID: NCT05897190 Completed - SARS-CoV-2 Clinical Trials

Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Vaccine Booster

Start date: May 16, 2022
Phase: Phase 1
Study type: Interventional

This study is to evaluate the safety and immunogenicity of a SARS-CoV-2 mRNA Vaccine as a heterologous booster dose in adults who completed 2 doses of inactivated vaccination through 12 months in China.

NCT ID: NCT05894590 Completed - SARS-CoV-2 Clinical Trials

Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19

Start date: November 15, 2022
Phase:
Study type: Observational

The goal of this study is to assess serious adverse events associated with hospitalizations in the non-acute phase after vaccination with the mRNA-1273 vaccine in persons with underlying diseases who are considered to have a high risk of severe exacerbation of COVID-19.

NCT ID: NCT05894525 Completed - SARS-CoV-2 Clinical Trials

Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine

Start date: November 15, 2022
Phase:
Study type: Observational

The goal of this study is to assess the adverse events in the acute phase observed after vaccination with the mRNA-1273 vaccine in persons with underlying diseases who are considered to have a high risk of severe exacerbation specified in COVID-19.

NCT ID: NCT05894499 Completed - SARS-CoV-2 Clinical Trials

Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19

Start date: November 15, 2022
Phase:
Study type: Observational

The goal of this study is to confirm the onset status of hypersensitivity reactions including shock and anaphylaxis observed after vaccination with this drug in persons with underlying diseases who are considered to have a high risk of severe exacerbation of COVID-19 and explore risk factors.

NCT ID: NCT05882383 Completed - SARS-CoV-2 Clinical Trials

Changes of Optical Quality During the Peak of the Covid-19 Pandemic

Start date: November 25, 2022
Phase:
Study type: Observational

To explore whether cornea structure, and optical quality are affected by the covid-19 infection.

NCT ID: NCT05876377 Recruiting - COVID-19 Clinical Trials

Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data

Start date: October 23, 2023
Phase:
Study type: Observational

This study aims to use vaccination information from state vaccine registries linked with HealthVerity insurance claims for the following: - to measure how effective the Pfizer-BioNTech vaccine is at preventing post-COVID conditions. - to understand characteristics of patients who are receiving COVID-19 vaccines. All patients whose information is kept unidentified in the HealthVerity database are eligible to be included for both aims of this study.

NCT ID: NCT05876364 Active, not recruiting - COVID-19 Clinical Trials

Study to Assess Safety, Reactogenicity and Immunogenicity of the repRNA(QTP104) Vaccine Against SARS-CoV-2(COVID-19)

Start date: November 19, 2021
Phase: Phase 1
Study type: Interventional

This study is to evaluate the safety, reactogenicity, and immunogenicity of the QTP104 vaccine against SARS-CoV-2 infection in healthy adults.

NCT ID: NCT05870839 Active, not recruiting - SARS-CoV-2 Clinical Trials

Study of VXCO-100, a SARS-CoV Candidate Vaccine in Healthy Adults in the United States

Start date: May 11, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and immunogenicity of ascending dose levels of VXCO-100 in healthy adults.

NCT ID: NCT05827926 Active, not recruiting - Influenza Clinical Trials

A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults

Start date: April 14, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The study is divided into 2 parts: Part 1 and Part 2. The purpose of Part 1 of this study is to generate sufficient safety, reactogenicity, and immunogenicity data to enable selection of an mRNA-1083 vaccine composition and dose level to evaluate in a subsequent Phase 3 clinical trial in adults. The purpose of Part 2 of this study is to generate safety and immunogenicity data for additional mRNA-1083 compositions and dose levels in young adults ≥18 years and <50 years of age.